Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST)

Lung Cancer

Volumn 87, Issue 1, 2015, Pages 65-72

  Rasmussen, Jakob F ^a   Siersma, V ^a   Pedersen, J H ^a   Brodersen, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adverse effects; Cancer screening; Computed tomography; Lung cancer; Psychosocial aspects; Randomized controlled trial; Spiral

Indexed keywords

ADULT; ANXIETY; ARTICLE; BEHAVIOR; CANCER SCREENING; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; CONSEQUENCES OF SCREENING LUNG CANCER; CONTROLLED STUDY; DANISH CITIZEN; FEMALE; HUMAN; HUMAN EXPERIMENT; LUNG CANCER; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SMOKING; SOCIAL ASPECT; SOCIAL STIGMA; STATISTICAL ANALYSIS; SYMPTOM; CLINICAL TRIAL; DENMARK; EARLY DIAGNOSIS; LUNG NEOPLASMS; MIDDLE AGED; PSYCHOLOGY; QUALITY OF LIFE; RISK FACTOR;

ADULT; ANXIETY; DENMARK; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84922238267     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.11.003     Document Type: Article

References (34)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365(5):395-409.
3. Field J.K., van Klaveren R., Pedersen J.H., Pastorino U., Paci E., Becker N., et al. European randomized lung cancer screening trials: post NLST. J Surg Oncol 2013, 108(5):280-286.
4. Pedersen J.H., Ashraf H., Dirksen A., Bach K., Hansen H., Toennesen P., et al. The Danish randomized lung cancer CT screening trial - overall design and results of the prevalence round. J Thorac Oncol 2009, 4(5):608-614.
5. Saghir Z., Dirksen A., Ashraf H., Bach K.S., Brodersen J., Clementsen P.F., et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax 2012, 67(4):296-301.
6. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme 2014, UK National Screening Committee, http://www.screening.nhs.uk/criteria.
7. Byrne M.M., Weissfeld J., Roberts M.S. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. Med Decis Mak 2008, 28(6):917-925.
8. van den Bergh K.A., Essink-Bot M.L., Borsboom G.J., Th S.E., Prokop M., de Koning H.J., et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer 2010, 102(1):27-34.
9. Brodersen J., Thorsen H., Kreiner S. Consequences of screening in lung cancer: development and dimensionality of a questionnaire. Value Health 2010, 13(5):601-612.
10. Brodersen J., Thorsen H. Consequences of Screening in Breast Cancer (COS-BC): development of a questionnaire. Scand J Prim Health Care 2008, 26(4):251-256.
11. Andersen E. A goodness of fit test for the Rasch model. Psychometrika 1973, 38(1):123-140.
12. Rasmussen J.F., Siersma V., Brodersen J. Short- and long term psychosocial consequences of false positive results in the Danish Randomised Controlled Lung Cancer CT-screening Trial (DLCST) 2014, [unpublished].
13. Dufouil C., Brayne C., Clayton D. Analysis of longitudinal studies with death and drop-out: a case study. Stat Med 2004, 23(14):2215-2226.
14. Rotnitzky A., Robins J. Analysis of semi-parametric regression models with non-ignorable non-response. Stat Med 1997, 16(1-3):81-102.
15. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 1995, 57(1):289-300.
16. Lindberg L.G., Svendsen M., Doemgaard M., Brodersen J. Better safe than sorry: a long-term perspective on experiences with a false-positive screening mammography in Denmark. Health Risk Soc 2013, 15(8):699-716.
17. Taylor K.L., Cox L.S., Zincke N., Mehta L., McGuire C., Gelmann E. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer 2007, 56(1):125-134.
18. Bach P.B., Mirkin J.N., Oliver T.K., Azzoli C.G., Berry D.A., Brawley O.W., et al. Benefits and harms of CT screening for lung cancer: a systematic reviewbenefits and harms of CT screening for lung cancer. JAMA 2012, 1-12.
19. Ashraf H., Saghir Z., Dirksen A., Pedersen J.H., Thomsen L.H., Dossing M., et al. Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme. Thorax 2014, 69(6):574-579.
20. Malmqvist J., Pedersen J.H., Siersma V., Heleno B., Thorsen H., Rasmussen J.F., et al. Selection bias in the control group in the Danish lung cancer screening trial 2014, [unpublished].
21. Saghir Z., Ashraf H., Dirksen A., Brodersen J., Pedersen J.H. Contamination during 4 years of annual CT screening in the Danish Lung Cancer Screening Trial (DLCST). Lung Cancer 2011, 71(3):323-327.
22. Hestbech M.S., Siersma V., Dirksen A., Pedersen J.H., Brodersen J. Participation bias in a randomised trial of screening for lung cancer. Lung Cancer 2011, 73(3):325-331.
23. van den Bergh K.A., Essink-Bot M.L., Borsboom G.J., Scholten E.T., van Klaveren R.J., de Koning H.J. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011, 38(1):154-161.
24. Taylor K.L., Shelby R., Gelmann E., McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 2004, 96(14):1083-1094.
25. Comins J., Brodersen J., Krogsgaard M., Beyer N. Rasch analysis of the Knee injury and Osteoarthritis Outcome Score (KOOS): a statistical re-evaluation. Scand J Med Sci Sports 2008, 18(3):336-345.
26. Hagell P., Tornqvist A.L., Hobart J. Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data. J Neurol 2008, 255(2):246-254.
27. Hobart J.C., Williams L.S., Moran K., Thompson A.J. Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke 2002, 33(5):1348-1356.
28. Wiebe S., Guyatt G., Weaver B., Matijevic S., Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 2003, 56(1):52-60.
29. Brodersen J., McKenna S.P., Doward L.C., Thorsen H. Measuring the psychosocial consequences of screening. Health Qual Life Outcomes 2007, 5:3.
30. Becker N., Motsch E., Gross M.L., Eigentopf A., Heussel C.P., Dienemann H., et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J Cancer Res Clin Oncol 2012, 138(9):1475-1486.
31. van Iersel C.A., de Koning H.J., Draisma G., Mali W.P., Scholten E.T., Nackaerts K., et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007, 120(4):868-874.
32. Rasmussen J.F., Siersma V., Pedersen J.H., Heleno B., Saghir Z., Brodersen J. Healthcare costs in the Danish randomised controlled lung cancer CT-screening trial: a registry study. Lung Cancer 2014, 83(3):347-355.
33. Kaerlev L., Iachina M., Pedersen J.H., Green A., Norgard B.M. CT-screening for lung cancer does not increase the use of anxiolytic or antidepressant medication. BMC Cancer 2012, 12(1):188.
34. McCaffery K.J., Barratt A.L. Assessing psychosocial/quality of life outcomes in screening: how do we do it better?. J Epidemiol Community Health 2004, 58(12):968-970.